New treatment regimen for Eylea in EUSeptember 14, 2018
The European Commission has approved a new treatment approach for aflibercept (Eylea) to enable clinicians to combine proactive treatment with early extension of the injection interval for patients with neovascular age-related macular degeneration (nAMD).
The new regimen allows clinicians already in the first year of treatment to extend patients’ individual injection intervals based on visual and/ or anatomic outcomes.
The new approach is based on results from the ALTAIR study, in which, after 52 weeks, 57% of the patients had their next regularly scheduled Eylea injection at an interval of 12 weeks or more. Treatment intervals up to 16 weeks between injections have been studied.
Patients participating in the study gained an average of up to 9.0 letters, including 50% of participants who gained 10 or more letters of vision at week 52, as measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart. These results were largely maintained during the second year, demonstrating the sustainability of this proactive approach.
Eylea has been approved in the majority of countries to treat patients with five indications: neovascular AMD (wet AMD), visual impairment due to diabetic macular edema (DME), retinal vein occlusion (RVO; branch RVO or central RVO) and myopic choroidal neovascularization.